Leerink lowered the firm’s price target on CVS Health (CVS) to $51 from $57 to account for the incremental uncertainty, while keeping a Market Perform rating on the shares. The firm is also ...
and consumer wellness offerings such as prescription and over-the-counter drugs, personal care, and beauty products. In the longer term, CVS stock is down nearly 30% on a YTD basis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback